Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing

Chengzu Long, Hui Li, Malte Tiburcy, Cristina Rodriguez-Caycedo, Viktoriia Kyrychenko, Huanyu Zhou, Yu Zhang, Yi Li Min, John M. Shelton, Pradeep P.A. Mammen, Norman Y. Liaw, Wolfram Hubertus Zimmermann, Rhonda Bassel-Duby, Jay W. Schneider, Eric N. Olson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Genome editing with CRISPR/Cas9 is a promising new approach for correcting or mitigating disease-causing mutations. Duchenne muscular dystrophy (DMD) is associated with lethal degeneration of cardiac and skeletal muscle caused by more than 3000 different mutations in the X-linked dystrophin gene (DMD). Most of these mutations are clustered in "hotspots." There is a fortuitous correspondence between the eukaryotic splice acceptor and splice donor sequences and the protospacer adjacent motif sequences that govern prokaryotic CRISPR/Cas9 target gene recognition and cleavage. Taking advantage of this correspondence, we screened for optimal guide RNAs capable of introducing insertion/deletion (indel) mutations by nonhomologous end joining that abolish conserved RNA splice sites in 12 exons that potentially allow skipping of the most common mutant or out-of-frame DMD exons within or nearby mutational hotspots. We refer to the correction of DMD mutations by exon skipping as myoediting. In proof-of-concept studies, we performed myoediting in representative induced pluripotent stem cells from multiple patients with large deletions, point mutations, or duplications within the DMD gene and efficiently restored dystrophin protein expression in derivative cardiomyocytes. In three-dimensional engineered heart muscle (EHM), myoediting of DMD mutations restored dystrophin expression and the corresponding mechanical force of contraction. Correcting only a subset of cardiomyocytes (30 to 50%) was sufficient to rescue the mutant EHM phenotype to near-normal control levels. We conclude that abolishing conserved RNA splicing acceptor/donor sites and directing the splicing machinery to skip mutant or out-of-frame exons through myoediting allow correction of the cardiac abnormalities associated with DMD by eliminating the underlying genetic basis of the disease.

Original languageEnglish (US)
Article numbereaap9004
JournalScience advances
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Duchenne Muscular Dystrophy
Muscular Dystrophies
Myocardium
Mutation
Dystrophin
Exons
Clustered Regularly Interspaced Short Palindromic Repeats
Cardiac Myocytes
Guide RNA
INDEL Mutation
Tissue Donors
RNA Splicing
Induced Pluripotent Stem Cells
X-Linked Genes
RNA Splice Sites
Inborn Genetic Diseases
Sequence Deletion
Gene Editing
Point Mutation
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. / Long, Chengzu; Li, Hui; Tiburcy, Malte; Rodriguez-Caycedo, Cristina; Kyrychenko, Viktoriia; Zhou, Huanyu; Zhang, Yu; Min, Yi Li; Shelton, John M.; Mammen, Pradeep P.A.; Liaw, Norman Y.; Zimmermann, Wolfram Hubertus; Bassel-Duby, Rhonda; Schneider, Jay W.; Olson, Eric N.

In: Science advances, Vol. 4, No. 1, eaap9004, 01.01.2018.

Research output: Contribution to journalArticle

Long, C, Li, H, Tiburcy, M, Rodriguez-Caycedo, C, Kyrychenko, V, Zhou, H, Zhang, Y, Min, YL, Shelton, JM, Mammen, PPA, Liaw, NY, Zimmermann, WH, Bassel-Duby, R, Schneider, JW & Olson, EN 2018, 'Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing', Science advances, vol. 4, no. 1, eaap9004. https://doi.org/10.1126/sciadv.aap9004
Long, Chengzu ; Li, Hui ; Tiburcy, Malte ; Rodriguez-Caycedo, Cristina ; Kyrychenko, Viktoriia ; Zhou, Huanyu ; Zhang, Yu ; Min, Yi Li ; Shelton, John M. ; Mammen, Pradeep P.A. ; Liaw, Norman Y. ; Zimmermann, Wolfram Hubertus ; Bassel-Duby, Rhonda ; Schneider, Jay W. ; Olson, Eric N. / Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. In: Science advances. 2018 ; Vol. 4, No. 1.
@article{1356c823daf44fb5abfd532c3fb5cc6f,
title = "Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing",
abstract = "Genome editing with CRISPR/Cas9 is a promising new approach for correcting or mitigating disease-causing mutations. Duchenne muscular dystrophy (DMD) is associated with lethal degeneration of cardiac and skeletal muscle caused by more than 3000 different mutations in the X-linked dystrophin gene (DMD). Most of these mutations are clustered in {"}hotspots.{"} There is a fortuitous correspondence between the eukaryotic splice acceptor and splice donor sequences and the protospacer adjacent motif sequences that govern prokaryotic CRISPR/Cas9 target gene recognition and cleavage. Taking advantage of this correspondence, we screened for optimal guide RNAs capable of introducing insertion/deletion (indel) mutations by nonhomologous end joining that abolish conserved RNA splice sites in 12 exons that potentially allow skipping of the most common mutant or out-of-frame DMD exons within or nearby mutational hotspots. We refer to the correction of DMD mutations by exon skipping as myoediting. In proof-of-concept studies, we performed myoediting in representative induced pluripotent stem cells from multiple patients with large deletions, point mutations, or duplications within the DMD gene and efficiently restored dystrophin protein expression in derivative cardiomyocytes. In three-dimensional engineered heart muscle (EHM), myoediting of DMD mutations restored dystrophin expression and the corresponding mechanical force of contraction. Correcting only a subset of cardiomyocytes (30 to 50{\%}) was sufficient to rescue the mutant EHM phenotype to near-normal control levels. We conclude that abolishing conserved RNA splicing acceptor/donor sites and directing the splicing machinery to skip mutant or out-of-frame exons through myoediting allow correction of the cardiac abnormalities associated with DMD by eliminating the underlying genetic basis of the disease.",
author = "Chengzu Long and Hui Li and Malte Tiburcy and Cristina Rodriguez-Caycedo and Viktoriia Kyrychenko and Huanyu Zhou and Yu Zhang and Min, {Yi Li} and Shelton, {John M.} and Mammen, {Pradeep P.A.} and Liaw, {Norman Y.} and Zimmermann, {Wolfram Hubertus} and Rhonda Bassel-Duby and Schneider, {Jay W.} and Olson, {Eric N.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1126/sciadv.aap9004",
language = "English (US)",
volume = "4",
journal = "Science advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science",
number = "1",

}

TY - JOUR

T1 - Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing

AU - Long, Chengzu

AU - Li, Hui

AU - Tiburcy, Malte

AU - Rodriguez-Caycedo, Cristina

AU - Kyrychenko, Viktoriia

AU - Zhou, Huanyu

AU - Zhang, Yu

AU - Min, Yi Li

AU - Shelton, John M.

AU - Mammen, Pradeep P.A.

AU - Liaw, Norman Y.

AU - Zimmermann, Wolfram Hubertus

AU - Bassel-Duby, Rhonda

AU - Schneider, Jay W.

AU - Olson, Eric N.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Genome editing with CRISPR/Cas9 is a promising new approach for correcting or mitigating disease-causing mutations. Duchenne muscular dystrophy (DMD) is associated with lethal degeneration of cardiac and skeletal muscle caused by more than 3000 different mutations in the X-linked dystrophin gene (DMD). Most of these mutations are clustered in "hotspots." There is a fortuitous correspondence between the eukaryotic splice acceptor and splice donor sequences and the protospacer adjacent motif sequences that govern prokaryotic CRISPR/Cas9 target gene recognition and cleavage. Taking advantage of this correspondence, we screened for optimal guide RNAs capable of introducing insertion/deletion (indel) mutations by nonhomologous end joining that abolish conserved RNA splice sites in 12 exons that potentially allow skipping of the most common mutant or out-of-frame DMD exons within or nearby mutational hotspots. We refer to the correction of DMD mutations by exon skipping as myoediting. In proof-of-concept studies, we performed myoediting in representative induced pluripotent stem cells from multiple patients with large deletions, point mutations, or duplications within the DMD gene and efficiently restored dystrophin protein expression in derivative cardiomyocytes. In three-dimensional engineered heart muscle (EHM), myoediting of DMD mutations restored dystrophin expression and the corresponding mechanical force of contraction. Correcting only a subset of cardiomyocytes (30 to 50%) was sufficient to rescue the mutant EHM phenotype to near-normal control levels. We conclude that abolishing conserved RNA splicing acceptor/donor sites and directing the splicing machinery to skip mutant or out-of-frame exons through myoediting allow correction of the cardiac abnormalities associated with DMD by eliminating the underlying genetic basis of the disease.

AB - Genome editing with CRISPR/Cas9 is a promising new approach for correcting or mitigating disease-causing mutations. Duchenne muscular dystrophy (DMD) is associated with lethal degeneration of cardiac and skeletal muscle caused by more than 3000 different mutations in the X-linked dystrophin gene (DMD). Most of these mutations are clustered in "hotspots." There is a fortuitous correspondence between the eukaryotic splice acceptor and splice donor sequences and the protospacer adjacent motif sequences that govern prokaryotic CRISPR/Cas9 target gene recognition and cleavage. Taking advantage of this correspondence, we screened for optimal guide RNAs capable of introducing insertion/deletion (indel) mutations by nonhomologous end joining that abolish conserved RNA splice sites in 12 exons that potentially allow skipping of the most common mutant or out-of-frame DMD exons within or nearby mutational hotspots. We refer to the correction of DMD mutations by exon skipping as myoediting. In proof-of-concept studies, we performed myoediting in representative induced pluripotent stem cells from multiple patients with large deletions, point mutations, or duplications within the DMD gene and efficiently restored dystrophin protein expression in derivative cardiomyocytes. In three-dimensional engineered heart muscle (EHM), myoediting of DMD mutations restored dystrophin expression and the corresponding mechanical force of contraction. Correcting only a subset of cardiomyocytes (30 to 50%) was sufficient to rescue the mutant EHM phenotype to near-normal control levels. We conclude that abolishing conserved RNA splicing acceptor/donor sites and directing the splicing machinery to skip mutant or out-of-frame exons through myoediting allow correction of the cardiac abnormalities associated with DMD by eliminating the underlying genetic basis of the disease.

UR - http://www.scopus.com/inward/record.url?scp=85042163565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042163565&partnerID=8YFLogxK

U2 - 10.1126/sciadv.aap9004

DO - 10.1126/sciadv.aap9004

M3 - Article

VL - 4

JO - Science advances

JF - Science advances

SN - 2375-2548

IS - 1

M1 - eaap9004

ER -